Jacobs Levy Equity Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Jacobs Levy Equity Management’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,245	Closed	-$154K	–	1151
2020 Q4	$154K	Sell	20,245 -42,976	-68%	-$288K	﹤0.01%	974
2020 Q3	$574K	Buy	63,221 +51,719	+450%	+$392K	0.01%	762
2020 Q2	$97K	Buy	+11,502	New	+$75.7K	﹤0.01%	1010

Other funds holding LOGC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Jacobs Levy Equity Management's LOGC Position: Q1 2021 in Review

Jacobs Levy Equity Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2021, closing a stake of 20,245 shares — an estimated $154K sold.

Jacobs Levy Equity Management first reported a position in LOGC in Q2 2020 and held it in 3 quarters. The position peaked at $574K in Q3 2020. 61 funds tracked by Wall St. Rank hold LOGC as of Q1 2021.

Jacobs Levy Equity Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 20,245 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $154K.
Jacobs Levy Equity Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
Jacobs Levy Equity Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $574K in Q3 2020.
61 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2021, filed 17 May 2021.